YOLFTbeta
Elicera Therapeutics AB

Elicera Therapeutics AB

ELIC · ST · Healthcare / Biotechnology

2.59SEK-0.02 (-0.58%)

Price History

Full chart

Market Stats

Previous Close2.60
Open2.60
Day Range2.54 – 2.71
52-Week Range2.25 – 7.58
Volume126.65K
Market Cap190.53M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.34
Dividend Yield0.00%
Beta0.29
50-Day Avg2.68
200-Day Avg3.93

About

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in late preclinical evaluation stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Johan Liwing
  • Employees3
  • HeadquartersWorld Trade Center Göteborg, Gothenburg, Sweden, 412 51, Sweden
  • Websitehttps://www.elicera.com

Leadership

  • Mr. Di YuCo-Founder, Acting Chief Scientific Officer, Chief Development Officer & Director · b. 1985
  • Prof. Magnus EssandChief Science Officer, Co-Founder & Director (Leave of Absence) · b. 1964
  • Mr. Johan LiwingChief Executive Officer · b. 1974
  • Mr. Ingvar KarlssonChief Financial Officer · b. 1956
  • Mr. Jamal El-Mosleh M.Sc.Executive Officer · b. 1981
  • Ms. Anna Koptina GultekinHead of Regulatory Affairs
  • Mr. Annu SuchdevHead of QA

Financials

Income Statement

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----005871.28M11.23M7.13M0
Growth (%)--------+217957.92%+777.34%-36.53%-100.00%
Cost of Revenue------11.78K11.78K11.78K11.78K11.79K-
Gross Profit-------11.78K-11.19K1.28M11.22M7.13M-
Gross Margin--------1906.13%100.01%99.89%100.00%-
Operating Expense------2.82M13.11M20.64M39.54M24.01M-
Operating Income583.40K548.18K-4.39K-3.65K-3.52K-194.25K-2.83M-13.12M-19.36M-28.33M-16.88M-17.94M
Operating Margin--------2234986.03%-1512.73%-252.24%-236.87%-
EBITDA583.40K548.18K-424-1.30K-3.52K-194.25K-2.82M-13.11M-19.43M-17.09M-16.82M-17.40M
EBITDA Margin--------2232980.07%-1517.73%-152.14%-236.00%-
Net Income454.17K427.84K-4.82K-4.96K-3.52K-187.88K-2.82M-13.12M-19.52M-16.40M-16.11M-17.41M
Net Income Margin--------2235169.17%-1524.61%-146.02%-226.01%-
Interest Expense---00001.07K129.34K75.89K52.85K7.88K
Interest Expense % of Total Revenue-------183.13%10.10%0.68%0.74%-

Balance Sheet

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets987.50K1.19M938.25K812.69K809.16K618.10K12.59M54.74M46.31M30.18M27.56M27.42M
Total Liabilities596.87K366.76K124.60K4.00K4.00K4.00K2.35M2.50M13.51M13.78M6.79M4.06M
Total Equity390.63K818.47K813.65K808.69K805.16K614.10K10.24M52.24M32.80M16.40M20.77M23.36M
Cash50.00K822.65K924.96K810.58K56.17K33.83K11.56M52.39M43.82M29.38M26.40M24.85M
Net Debt-50.00K-822.65K-924.96K-810.58K-56.17K-33.83K-11.56M-52.39M-43.82M-29.38M-26.40M-24.85M

Cash Flow

Currency: SEK2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow----239.16K-239.16K-239.16K-905.25K-14.29M-8.57M-14.92M-23.46M-21.55M
Investing Cash Flow---216.81K216.81K216.81K-8.88K-1.00K-483.17K-1.00K
Financing Cash Flow---12.45M12.45M12.45M12.45M55.12M--20.48M20.00M
Capital Expenditure00000058.88K001.00K04
Free Cash Flow------239.16K-964.13K-14.29M-8.57M-14.92M-23.46M-21.55M
FCF to OCF-----100.00%106.50%100.00%100.00%100.01%100.00%100.00%

Earnings

Report DateJun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Feb 17, 2023May 16, 2023Aug 29, 2023Nov 14, 2023Feb 13, 2024May 27, 2024Aug 29, 2024Sep 30, 2024Feb 3, 2025May 15, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------0.32--------------
EPS Actual-0.15-0.33-0.11-0.23-0.18-0.35-0.20-0.11-0.22-0.26-0.24-0.26-0.16-0.07-0.07-0.22-0.050.01-0.14-0.10-0.12
Surprise------37.50%--------------
Timing------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-----

Key Statistics & Ratios

Market Cap190.53M
Enterprise Value122.73M
Trailing P/E0.00
Forward P/E0.00
Price / Sales24.45
Price / Book3.21
EPS-0.34
Book Value0.843
Revenue (TTM)7.79M
Gross Profit (TTM)7.79M
EBITDA-17.93M
Profit Margin-230.77%
Operating Margin4270.38%
Return on Equity-41.69%
Return on Assets-22.89%
Shares Outstanding66.74M
Shares Float47.62M
Beta0.29
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 11, 202639:38